Axogen to Participate in the 75th Annual American Society for Surgery of the Hand Meeting
September 24 2020 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or discontinuity
to peripheral nerves, announced that it will participate in the
75th Annual Meeting of the American Society for Surgery of the Hand
(ASSH) being held virtually from October 1-3, 2020. The meeting
will feature live and on-demand scientific sessions, training
opportunities, and a virtual solutions center.
Axogen’s peripheral nerve repair portfolio will be featured
throughout the clinical and scientific sessions including key
presentations highlighting the clinical and economic value of
Avance Nerve Graft as compared to traditional nerve autograft:
- The latest clinical data from the
MATCHSM autograft cohort of the RANGER® Registry will be presented
comparing Avance Nerve Graft repairs to autograft repairs in
sensory and mixed nerve injuries of the upper extremity. The study
included 156 nerve repairs and found that sensory and motor
clinical outcomes for Avance Nerve Graft were comparable to those
reported for nerve autograft.
- Complementing the MATCH clinical
outcomes, a study on nerve repair procedure costs will also be
presented. The study evaluated payor data from 340 individual
claims and found that hospital facility procedure costs for Avance
Nerve Graft were comparable to that of traditional nerve
autograft.
“We are excited to share clinical data showing the important
clinical and economic value that Avance Nerve Graft provides to
surgeons and patients to aid clinical decision making when
selecting between Avance and autograft,” said Karen Zaderej,
chairman, CEO, and president. “Avance provides comparable clinical
outcomes and hospital facility procedural costs without the loss of
function and risks associated with the autograft harvest.”
As a Premium Solutions Provider for the meeting, Axogen will
host a pre-meeting symposium on Tuesday, September 29 from 8:00
p.m. – 9:00 p.m. CST. The symposium, Nerve Repair
Live, will be held virtually and feature live simulated
surgical demonstrations. Participants will have the opportunity to
engage and interact with faculty through live polling and Q&A
while nerve repair techniques are demonstrated in real time.
Additionally, the virtual Solutions Center will feature Axogen’s
comprehensive platform for nerve repair and attendees will have the
opportunity to chat live with Axogen scientists, clinicians, and
other experts to learn more about innovative surgical solutions for
peripheral nerve repair.
“We look forward to engaging virtually with our surgeon
customers at the ASSH meeting to discuss how and when they use our
nerve repair product portfolio to help patients with peripheral
nerve damage,” added Zaderej. “As always, we strive to provide
excellent clinical and educational experiences for surgeons. This
year, we converted our surgeon education programs to virtual
platforms and launched an interactive webinar series. We are
confident we will provide high value engagements and interactions
for everyone involved.”
About the RANGER RegistryThe
RANGER registry, a multicenter Registry of Avance Nerve Graft's
Utilization and Recovery Outcomes Post Peripheral Nerve
Reconstruction, is an active, multicenter clinical registry
designed to continuously monitor and collect injury, repair,
safety, and outcomes data for peripheral nerve injuries repaired
with processed nerve allograft (Avance Nerve Graft), nerve
autograft, and manufactured conduits. The study, launched in 2008,
includes more than 30 centers. RANGER is an Axogen sponsored
ongoing open label registry study. Each patient outcome is
dependent upon the nature and extent of nerve loss or damage,
timing between nerve loss and repair, and the natural course of the
patient’s recovery.
About MATCHMATCH is a
contemporary cohort control for the RANGER study. MATCH provides
reference controls for nerve autograft and manufactured conduits
from participating registry centers.
About Avance Nerve GraftAvance Nerve Graft is a
biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site. Avance provides structural
support for regenerating axons, and revascularizes and remodels
into the patient’s own tissue. It is available in a variety of
lengths and diameters.
About ASSHThe American Society for Surgery of
the Hand is the oldest medical society dedicated to the hand and
upper extremity. Its mission is to advance the science and practice
of hand and upper extremity surgery through education, research,
and advocacy on behalf of patients and practitioners. For more
information, please visit www.assh.org.
About AxogenAxogen (AXGN) is the leading
company focused specifically on the science, development and
commercialization of technologies for peripheral nerve regeneration
and repair. Axogen employees are passionate about helping to
restore peripheral nerve function and quality of life to patients
with physical damage or transection to peripheral nerves by
providing innovative, clinically proven and economically effective
repair solutions for surgeons and health care providers. Peripheral
nerves provide the pathways for both motor and sensory signals
throughout the body. Every day, people suffer traumatic injuries or
undergo surgical procedures that impact the function of their
peripheral nerves. Physical damage to a peripheral nerve, or
the inability to properly reconnect peripheral nerves, can result
in the loss of muscle or organ function, the loss of sensory
feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments; Axoguard® Nerve Cap, a
porcine submucosa ECM product used to protect a peripheral nerve
end and separate the nerve from the surrounding environment to
reduce the development of symptomatic or painful neuroma; and
Avive® Soft Tissue Membrane, a processed human umbilical cord
intended for surgical use as a resorbable soft tissue barrier. The
Axogen portfolio of products is available in the United States,
Canada, the United Kingdom, South Korea, and several other European
and international countries.
Contact:Axogen, Inc.Peter Mariani, Chief Financial
OfficerInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024